The Potency of a KRAS Silent Variant.

doi:10.1056/NEJMcibr2202981

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Community

Back to search

Article

The Potency of a KRAS Silent Variant.

The New England journal of medicine - 30 Jun 2022

Molina-Arcas Miriam, Downward Julian

Abstract excerpt

No abstract is available from the source.

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genetic Variation
Share to Mutation
Share to Proto-Oncogene Proteins p21(ras)
Share to ras Proteins

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Source

Open in PubMed

Identifiers

PMID: 35767444
DOI: 10.1056/NEJMcibr2202981

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 8 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

The Potency of a KRAS Silent Variant.PMID 35767444Read ↗

KRAS mutation detection: a new look at an old gene.Semantic proximity Read ↗

Targeting KRAS: Good, But Is It Good Enough?Semantic proximity Read ↗

A deCIDEdly New Germline Mutation That Protects Against Liver Disease.Semantic proximity Read ↗

Tracing the origins of KRAS oncogene addiction.Semantic proximity Read ↗

A bright future for KRAS inhibitors.Semantic proximity Read ↗

KRAS Alleles: The Devil Is in the Detail.Semantic proximity Read ↗

Expanding the options for KRAS inhibition.Semantic proximity Read ↗

Genetics: Fitness depends on KRAS imbalance.Semantic proximity Read ↗

Human cell line model for cancer-associated KRAS noncoding SNP.Semantic proximity Read ↗

Sweeping KRAS generalizations: are we depriving patients of an effective treatment? A novel KRAS mutation and dramatic response to panitumumab in a patient with metastatic colorectal cancer.Semantic proximity Read ↗

Beyond the KRAS test.Semantic proximity Read ↗

The price of silent mutations.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.